Communicators

Medigene AG: Medigene participates at upcoming conferences

Planegg (22.02.2019) - Medigene AG (FSE: MDG1, Prime Standard, SDAX) today announced its participation at the following upcoming scientific conferences:

ACUTE LEUKEMIAS XVII

Date: 24 - 27 February

Location: Munich, Germany

Whistler Conference Centre

Date: 10 - 14 March 2019

Location: Whistler, Canada

Immuno Oncology Summit Europe

Date: 18 - 22 March 2019

Location: London, UK

Dr Slavoljub Milosevic will give a presentation on "Rapid High-Throughput Functional Selection of Neoantigens and Assessment of Their Safety" on 18 March 2019

9th Gene Quantification Event qPCR dPCR & NGS 2019

Symposium & Industrial Exhibition & Application Workshops

Date: 18 - 22 March 2019

Location: Freising-Weihenstephan, Germany

International Cellular Therapy Symposium 2019

Date: 22 - 23 March 2019

Location: Erlangen, Germany

Dr. Daniel Sommermeyer will give a poster presentation on "HA-1-specific T-cell receptors for the treatment of hematological malignancies" on 22 March 2019

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, SDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.

For more information, please visit http://www.medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Contact Medigene AG

Julia Hofmann, Dr. Robert Mayer

Tel.: +49 - 89 - 20 00 33 - 33 01

email: investor@medigene.com

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.

(end)

emitter: Medigene AG

address: Lochhamer Straße 11, 82152 Planegg

country: Germany

contact person: Medigene PR/IR

phone: +49 89 2000 33 3301

e-mail: investor@medigene.com

website: www.medigene.de